Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Imnovid 4 mg hard capsules, JAMP Pomalidomide, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Imnovid 2 mg hard capsules, JAMP Pomalidomide, Imnovid 1 mg hard capsules, JAMP Pomalidomide, Dexamethason 4 mg JENAPHARM®, Imnovid 3 mg hard capsules, Pomalidomide Adalvo 4 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Isatuximab, Isatuximab, JAMP Pomalidomide, Imnovid 3 mg hard capsul
Sanofi-aventis Healthcare Pty Ltd
Cancer
1 trial -
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
Bayer AG
"Patients with interstitial lung disease associated pulmonary hypertension"
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Hidradenitis Suppurativa
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Acne Vulgaris
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Ichthyosis
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Palmoplantar Pustulosis
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Generalized Pustular Psoriasis
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Acneiform Eruptions
1 trial -
Induction therapy of GP(Pomalidomide+Obinutuzumab)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indolent Lymphoma
1 trial -
Inetetamab
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Infigratinib is provided as a single dose of minitablets for oral administration
BridgeBio Oncology Therapeutics
Achondroplasia
1 trial -
Inflectra 100 mg powder for concentrate for solution for infusion, Inflectra 100 mg powder for concentrate for solution for infusion, AZD0171, Oleclumab, Mycophenolate Mofetil 250 mg Capsules, Inflectra 100 mg powder for concentrate for solution for infusion, CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., volrustomig, CISPLATIN , Monalizumab, Datopotamab deruxtecan, Inflectra 100 mg powder for concentrate for solution for infusion, Rilvegostomig, Inflectra 100 mg powder for concentra
AstraZeneca AB
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
1 trial -
Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508
Lacuna Pharma Pty Ltd
Thromboembolic disease
1 trial -
Injectable suspension of allogeneic adult mesenchymal stem cells
Lxo Ireland Designated Activity Company
Hidradenitis Suppurativa
1 trial -
Injection of IAH0968+Gemcitabine+Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HER2 Gene Mutation
1 trial -
Inlyta 1 mg film-coated tablets, Inlyta 3 mg film-coated tablets, CELLTOP 50 mg, capsule molle, ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion
ISTA Pharma Limited
Ependymoma, Medulloblastoma
1 trial -
Inotuzumab Ozogamicin±Donor Lymphocyte Infusion
The First People's Hospital of Lianyungang
Leukemia, Lymphocytic, Acute
1 trial -
Inotuzumab ozogamicin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Lymphocytic Leukemia
1 trial -
Insulin lispro
HALOZYME THERAPEUTICS, INC.
Diabetes Mellitus, Type II
1 trial -
Insulin lispro
HALOZYME THERAPEUTICS, INC.
Diabetes Mellitus, Type 1
2 trials -
Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone.
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Metastatic Castration-resistant Prostate Cancer
1 trial -
Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir
The First People's Hospital of Lianyungang
Leptomeningeal Metastasis of HER2-positive Breast Cancer
1 trial -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Iomab-B
Actinium Pharmaceuticals
Non Hodgkin Lymphoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources